Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2024. Leap ...

Around half of NSCLC patients experience severe muscle wasting, known as cachexia, which limits treatment options and worsens prognosis. The research involved a cohort of 55 patients with metastatic ...

NEW YORK, Nov. 12, 2024 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global Glaucoma Therapeutics Market is experiencing significant growth owing to the ...

NORTHBROOK, Ill., Nov. 12, 2024 /PRNewswire/ -- Endevica Bio's experimental peptide to prevent weight loss associated with ...

Currently, there is no FDA-approved treatment for cancer anorexia cachexia syndrome. ART26.12, Artelo's lead Fatty Acid ...

Pfizer's head of digital devices says the industry is close to a 'revolution' in using measures from wearables in clinical ...

Ponsegromab increased weight and activity levels in cachexia patients, confirming GDF-15 as a key driver and therapeutic ...